New drug combo targets deadly brain TB in landmark trial
NCT ID NCT07350174
First seen Jan 28, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This study tests a new two-drug combination (Alpibectir and Ethionamide) added to standard treatment for tuberculosis meningitis, a serious brain infection. Researchers will measure how well the drugs reach the brain and their safety in 64 newly diagnosed patients. The trial also checks how the drugs affect HIV treatment in patients who are HIV-positive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS MENINGITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.